PAYVANDI, FLORA
PAYVANDI, FLORA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors
2024 G. Castaman, F. Peyvandi, J.A. Kremer Hovinga, R.E.G. Schutgens, S. Robson, K. Moreno, V. Jiménez-Yuste
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies
2024 G. Di Minno, W. Miesbach, G. Castaman, F. Peyvandi
Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B
2024 R. Lemons, M. Wang, J. Curtin, L.M. Lepatan, C. Male, F. Peyvandi, M. von Depka Prondzinski, R. Wang, W. Mckeand, W. Seifert, J. Oldenburg
Real-world experience of rIX-FP prophylaxis at dosing intervals of 14 days or more in adult patients with haemophilia B in Italy - Results from IDEAL Part B
2024 A. Coppola, F. Peyvandi, L. Banov, D. Cultrera, M. Margaglione, A. Tosetto, L. Valdrè, I. Schiavetti, A. Loraschi, G. Castaman
Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A
2024 L. Malec, F. Peyvandi, A.K.C. Chan, C. Königs, B. Zulfikar, H. Yuan, M. Simpson, M.T. Álvarez Román, M. Carcao, J.M. Staber, A.L. Dunn, S. Chou, R. D'Oiron, M. Albisetti, M. Demissie, E. Santagostino, A. Yarramaneni, N. Wong, L. Abad-Franch, S. Gunawardena, K. Fijnvandraat
Type 2M/2A von Willebrand disease: a shared phenotype between type 2M and 2A
2024 O. Seidizadeh, L. Mollica, S. Zambarbieri, L. Baronciani, A. Cairo, P. Colpani, G. Cozzi, M.T. Pagliari, A. Ciavarella, S.M. Siboni, F. Peyvandi
Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial
2024 G. Kenet, B. Nolan, B. Zulfikar, B. Antmen, P. Kampmann, T. Matsushita, C. You, K. Vilchevska, C.N. Bagot, A. Sharif, F. Peyvandi, G. Young, C. Negrier, J. Chi, B. Kittner, C. Sussebach, F. Shammas, B. Mei, S. Andersson, K. Kavakli
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial
2024 S.W. Pipe, P. Collins, C. Dhalluin, G. Kenet, C. Schmitt, M. Buri, V. Jiménez-Yuste, F. Peyvandi, G. Young, J. Oldenburg, M.E. Mancuso, K. Kavakli, A. Kiialainen, S. Deb, M. Niggli, T. Chang, M. Lehle, K. Fijnvandraat
Pattern of use and clinical outcomes with rIX‐FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real‐world study
2024 P. Giordano, B. Pollio, G. Sottilotta, C. Biasoli, F. Daniele, R. De Cristofaro, F. Peyvandi, M.R. Villa, G. Castaman
A case of lymphadenopathies with concomitant multiple acquired hemostasis disorders in an adult female patient
2024 A. Truma, A. Artoni, J.A. Giannotta, M. Caronni, F. Peyvandi
Application of genetic testing for the diagnosis of von Willebrand disease
2024 O. Seidizadeh, L. Baronciani, D. Lillicrap, F. Peyvandi
Safety and efficacy of combined dual antiplatelet therapy and factor VIII prophylaxis in patients with haemophilia A after acute coronary syndrome
2024 P. Agosti, S.M. Siboni, A. Ciavarella, S. Arcudi, F. Boggio, R. Gualtierotti, F. Peyvandi
Variant p.Tyr1584Cys: a frequent von Willebrand factor variant in search of von Willebrand disease
2024 O. Seidizadeh, L. Baronciani, P. Colpani, G. Cozzi, A. Ciavarella, S.M. Siboni, F. Peyvandi
Predicting inhibitor development using a random peptide phage-display library approach in the SIPPET cohort
2024 S. Hassan, G. Baselli, L. Mollica, R.L. Rossi, H. Chand, A. El-Beshlawy, M. Elalfy, V. Ramanan, P. Eshghi, M. Karimi, R. Palla, F.R. Rosendaal, F. Peyvandi
Landmark endorsement of a global registry: The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), publicly endorses World Federation of Hemophilia Gene Therapy Registry as global standard
2024 B.A. Konkle, F. Peyvandi, D. Coffin, M. Naccache, T. Youttananukorn, G.F. Pierce
Congenital fibrinogen disorders: a retrospective clinical and genetic analysis of the Prospective Rare Bleeding Disorders Database
2024 S. Mohsenian, R. Palla, M. Menegatti, A. Cairo, A. Lecchi, A. Casini, M. Neerman-Arbez, R. Asselta, S. Scardo, S.M. Siboni, J. Blatny, O. Zapletal, J. Schved, M. Giansily-Blaizot, S. Halimeh, M.A. Daoud, H. Platokouki, H. Pergantou, R.E.G. Schutgens, M. Van Haaften-Spoor, P. Brons, B. Laros-van Gorkom, E. Van Pinxten, M. Borhany, N. Fatima, D. Mikovic, M. Saracevic, G.N. Özdemir, Y. Ay, M. Makris, C. Lockley, A. Mumford, A. Harvey, S. Austin, A. Shapiro, A. Williamson, C. Mcguinn, I. Goldberg, P. De Moerloose, F. Peyvandi
Bleeding and thrombotic events and intensity of heparin therapy in the two first waves of COVID-19
2024 R. Rossio, M. Tettamanti, A.A. Galbussera, R. Gualtierotti, A. Giachi, A. Torri, N. Montano, A.L. Fracanzani, A. Bandera, A. Nobili, F. Peyvandi
Gender equity in hemophilia: need for healthcare, familial, and societal advocacy
2024 R. Gualtierotti, I. Garagiola, M. Mortarino, S. Spena, O. Romero-Lux, F. Peyvandi
Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A
2024 S. Agarwal, C. Hermans, W. Miesbach, F. Peyvandi, R. Sidonio, D. Osmond, V. Newman, J. Henshaw, S. Pipe
Recommendations for a minimum data set for monitoring gene therapy in hemophilia: communication from the ISTH SSC Working Group on Gene Therapy
2024 W. Miesbach, B. Konkle, P. Chowdary, R. Kaczmarek, F. Leebeek, J. Mahlangu, M. Makris, S.W. Pipe, A. Srivastava, J. Voorberg, G.F. Pierce, F. Peyvandi